Searched query = "Primary sclerosing cholangitis", "PSC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|1||JPRN-jRCTs051180120||01/04/2012||13/03/2019||Examination of the mizoribine and azathioprine combination immunosuppressive therapy in primary sclerosing cholangitis||Examination of the immunosuppressive drug combination therapy in primary sclerosing cholangitisStudy of the mizoribine and azathioprine combination immunosuppressive therapy - Examination of the immunosuppressive drug combination therapy in primary sclerosing cholangitis||Primary sclerosing cholangitis; PSC;K830||1 MZR|
Daily intake of mizoribine once before breakfast. Dose adjustment is done to achieve a blood concentration level over 3.0 microg/ml at 3 hour after meal.
Daily intake of azathioprine once after breakfast and once after dinner.
Starting dose is 0.5-1.0mg/kg daily (max 2.0mg) , is increased according to the condition of patients. Dose is adjusted to achieve WBC 3000-5000/m3, neutrophils 2000-3500/m3(the dose of 6MP is appotoimatery half of azathioprine). Continue the dosage during a study period.
|Tajiri Hitoshi||NULL||Recruiting||3age||18age||Both||10||Phase 2||Japan|
|2||JPRN-UMIN000029482||2012/04/01||10/10/2017||Study of combination immunosuppressive therapy in primary sclerosing cholangitis - A multicenter study for combination immunosuppressive therapy with mizoribine and azathioprine -||Study of combination immunosuppressive therapy in primary sclerosing cholangitis - A multicenter study for combination immunosuppressive therapy with mizoribine and azathioprine - - Study of combination immunosuppressive therapy in primary sclerosing cholangitis||Primary sclerosing cholangitis||Administration of mizoribine and azathioprine||Osaka General Medical Center||NULL||Complete: follow-up continuing||Not applicable||Not applicable||Male and Female||10||Not selected||Japan|